Established in 2008, Beijing Kangleweishi Biotechnology Co., Ltd. (hereafter referred to as Kangleweishi) is an innovation-driven biopharmaceutical company engaged in the research, development and industrialization of new vaccines. It has leading core technology and research and development capabilities at home and abroad in the development of new recombinant HPV vaccines.

Based on the biomedical manufacturing industry, the company has established a high-quality R&D team led by Professor Chen Xiaojian, with outstanding experts and scholars in the fields of biomedicine such as Liu Yongjiang and Zhang Haijiang.

Kangleweishi use its own resources and technological advantages to develop recombinant protein-based biological products based on structural design. At present, the HPV trivalent vaccine developed by the company has completed preclinical research work and has submitted a clinical trial registration application to the National Drug Administration System. It is expected that clinical approval will be obtained in the near future and clinical trials will be initiated immediately. Also, the company's other recombinant protein drug project research and development work is progressing in an orderly manner.